title: Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence?
abstract: Paraneoplastic neurological syndromes constitute an unusual manifestation of cancer. The objective of this case report is to debate the association between rituximab therapy and Guillain-Barre syndrome. We present the case of a 57 years old patient, with diffuse large-B cell lymphoma in complete remission, who consulted our hospital because of symmetric lower extremity weakness, developed while being treated with a rituximab maintenance schedule. Our main conclusion is that plasma cell dysregulation due to rituximab should be clarified in future studies.
authors.affiliation: Medical Oncology Department, Virgen Arrixaca University Hospital, Murcia, Spain. trebla_albert@hotmail.com
authors.forename: Alberto
authors.initials: A
authors.lastname: Carmona
authors.forename: Juan Domingo
authors.initials: JD
authors.lastname: Alonso
authors.forename: Manuel
authors.initials: M
authors.lastname: de las Heras
authors.forename: Agustín
authors.initials: A
authors.lastname: Navarrete
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D020275:Guillain-Barre Syndrome / Q000175:diagnosis / Q000209:etiology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes; D011241:Prednisone / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D013156:Splenectomy; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone